This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Our concerns regarding the article by Dr Backonja and colleagues¹ on gabapentin for treatment of painful diabetic neuropathy are related to how data on patient interpretation and recording of pain are statistically analyzed, as well as how clinical rather than statistical significance of improvement on pain scores is determined.

We appreciate the difficulties in performing pain research and the complexities inherent in the analysis of health-related quality-of-life questionnaires. The primary outcome measure (Likert Pain Scale), however, is essentially categorical data and yet is analyzed as if it were numerical. The scale uses numbers that correlate with the severity of pain but could just as well have used letters from A-K. In other words, the numbers stand for categories of pain, and the distance between them cannot be assumed to be uniform. To treat these numbers as statistically or mathematically meaningful is incorrect. Just as we would not . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects
Raskin et al.
Neurology 2004;63:865-873.
ABSTRACT | FULL TEXT  

Gabapentin in Pain Management
Mao and Chen
Anesth. Analg. 2000;91:680-687.
FULL TEXT